Therapeutic drug monitoring of depression – Amplification by magnesium ions

Radziwoń-Zaleska, Maria; Ryszewska-Pokraśniewicz, Beata; Skalski, Michał; Skrzeszewski, Jakub; Drozdowicz, Ewa; Nowak, Gabriel; Pilc, Andrzej; Bałkowiec-Iskra, Ewa

doi:10.1016/j.pharep.2015.06.109

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the limited effectiveness of antidepressant treatment, there is a great need for developing novel, satisfactory therapies. To date, there have been few clinical studies on magnesium supplementation in depressive disorders, and their findings have been inconclusive [ 34 , 35 , 36 ]. Therefore, the purpose of our study was to assess the efficacy and safety of antidepressant treatment accompanied with magnesium supplements.…”

Section: Introductionmentioning

confidence: 99%

Effects of Magnesium Supplementation on Unipolar Depression: A Placebo-Controlled Study and Review of the Importance of Dosing and Magnesium Status in the Therapeutic Response

Ryszewska-Pokraśniewicz¹,

Mach

Skalski

et al. 2018

Nutrients

Self Cite

View full text Add to dashboard Cite

Animal studies using tests and models have demonstrated that magnesium exerts an antidepressant effect. The literature contains few studies in humans involving attempts to augment antidepressant therapy with magnesium ions. The purpose of our study was to assess the efficacy and safety of antidepressant treatment, in combination with magnesium ions. A total of 37 participants with recurrent depressive disorder who developed a depressive episode were included in this study. As part of this double-blind study, treatment with the antidepressant fluoxetine was accompanied with either magnesium ions (120 mg/day as magnesium aspartate) or placebo. During an 8-week treatment period, each patient was monitored for any clinical abnormalities. Moreover, serum fluoxetine and magnesium levels were measured, and pharmaco-electroencephalography was performed. The fluoxetine + magnesium and fluoxetine + placebo groups showed no significant differences in either Hamilton Depression Rating Scale (HDRS) scores or serum magnesium levels at any stage of treatment. Multivariate statistical analysis of the whole investigated group showed that the following parameters increased the odds of effective treatment: lower baseline HDRS scores, female gender, smoking, and treatment augmentation with magnesium. The parameters that increased the odds of remission were lower baseline HDRS scores, shorter history of disease, the presence of antidepressant-induced changes in the pharmaco-EEG profile at 6 h after treatment, and the fact of receiving treatment augmented with magnesium ions. The limitation of this study is a small sample size.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of Magnesium Supplementation on Unipolar Depression: A Placebo-Controlled Study and Review of the Importance of Dosing and Magnesium Status in the Therapeutic Response

Ryszewska-Pokraśniewicz¹,

Mach

Skalski

et al. 2018

Nutrients

Self Cite

View full text Add to dashboard Cite

show abstract

“…Study subjects were examined by the same physician at consecutive time points: prior to treatment initiation (at baseline); 6 h after the first dose (maximum blood levels after the first dose); at 24 h; and 2, 4, 6, and 8 weeks after the first dose. The preliminary results of this study were reported elsewhere [15,24,26,27].…”

Section: Methodsmentioning

confidence: 58%

“…Previous study results [11,[22][23][24][25][26][27][28] give us hope for the usefulness of pharmaco-EEG as a tool for assessing the response to treatment.…”

Section: Introductionmentioning

confidence: 99%

Pharmaco-Electroencephalography-Based Assessment of Antidepressant Drug Efficacy—The Use of Magnesium Ions in the Treatment of Depression

Skalski

Mach

Januszko

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

Pharmaco-electroencephalography (pharmaco-EEG) is a technique used to assess the effects of psychotropic medications on the bioelectrical activity of the brain. The purpose of this study was to assess the treatment response with the use of the Hamilton Depression Rating Scale (HDRS) and via EEG. Over an 8-week period, we analyzed electroencephalographic tracings of 91 patients hospitalized for major depression at the Medical University of Warsaw. Thirty-nine of those patients received tricyclic antidepressants (TCAs), 35 received fluoxetine, and 17 received fluoxetine augmented with magnesium (Mg) ions. All patients had their serum drug levels monitored. The highest proportion of patients (88.2%) who showed adequate responses to treatment was observed in the fluoxetine+Mg group, whereas the lowest rates of treatment response were observed in the TCA group (58.3%). This difference was statistically significant (p = 0.029, Phi = 0.30). Our study demonstrated a relationship between achieving remission (HDRS ≤ 6 at week 8 of treatment) and obtaining a positive pharmaco-EEG profile 6 h after administration of the first dose in the group receiving fluoxetine augmented with Mg ions (p = 0.035, Phi = 0.63).

show abstract

Therapeutic drug monitoring of depression – Amplification by magnesium ions

Cited by 2 publications

References 0 publications

Effects of Magnesium Supplementation on Unipolar Depression: A Placebo-Controlled Study and Review of the Importance of Dosing and Magnesium Status in the Therapeutic Response

Effects of Magnesium Supplementation on Unipolar Depression: A Placebo-Controlled Study and Review of the Importance of Dosing and Magnesium Status in the Therapeutic Response

Pharmaco-Electroencephalography-Based Assessment of Antidepressant Drug Efficacy—The Use of Magnesium Ions in the Treatment of Depression

Contact Info

Product

Resources

About